| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Center for Blood Research, Harvard Medical School, Boston, MA 02115
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
T cells. Recently, the molecular pathways involved in
the induction of cell death by granzyme B, a protease with Aspase
activity, have begun to be identified. Granzyme B cleaves members of
the caspase family of cysteine proteases, thereby activating a
ubiquitous apoptotic cascade (15). Evidence from transfection experiments and knockout mice rendered deficient in perforin, granzyme A, or B suggests that granzyme A or B can independently with perforin induce target cell apoptosis (2, 16, 17, 18, 19, 20, 21). Granzyme A-deficient mice are defective in their ability to protect against hepatic failure and death from ectromelia, a cytopathic mousepox virus. The functional importance of granzyme A was also demonstrated in a murine CTL line, stably transfected with granzyme A antisense cDNA, which had 3- to 10-fold reduced granzyme A activity and induced 50 to 70% less cytolysis and DNA fragmentation in target cells (22).
Granzyme A, the most abundant of the proteases in human CTL granules, is a tryptic protease that cleaves synthetic substrates with Lys or Arg at the P1 position (11, 23). Granzyme A is unique among the granzymes in forming a disulfide-linked homodimer of approximately 50 kDa (24). Like granzyme B, it is produced in CTL as a proenzyme, which can be activated by dipeptidyl peptidase I cleavage of an activation dipeptide (25). It is stored in its cleaved active form in the acidic granules of cytotoxic cells, at a pH at which it is inactive.
We have produced in Escherichia coli a soluble and active
form of granzyme A (rGranA) that recognizes and cleaves known granzyme
A synthetic substrates, is inhibited by known inhibitors of native
granzyme A, and is recognized by a conformational Ab raised to native
granzyme A (26). Using affinity chromatography with a Ser
Ala mutant
of granzyme A (SArGranA), we previously identified two ubiquitous
proteins, PHAP3 I
(I1PP2A or mapmodulin) and PHAP II (set, TAF-1,
or I2PP2A), which bind to granzyme A (27, 28, 29, 30, 31, 32).
PHAP II is a substrate for granzyme A and is degraded within minutes of
CTL attack (26). In this study, we describe the interaction of granzyme
A with the monomer and dimer of the small heat shock protein hsp27.
Hsp27, a widely expressed phosphoprotein induced by heat shock and
other stressors, has been implicated as a molecular chaperone and as a
regulator of the cytoskeleton by binding to the actin cap (33, 34, 35). It
is rapidly phosphorylated at Ser78 and Ser82 in
response to serum, phorbol ester, calcium ionophore, bombesin,
thrombin, bradykinin, fibroblast growth factor, leukemia inhibitory
factor, high density lipoprotein, TNF, and IL-1 (35, 36, 37). In one
report, the overexpression of hsp27 in a breast cancer cell line
increased its susceptibility to cytolysis by T cells
(38).
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
ArGranA
Human pro-rGranA was expressed in E. coli from a
pet26b plasmid (Novagen, Madison, WI) with an enterokinase site 5' of
the predicted first amino acid of the active enzyme (rGranA) for in
vitro activation and a C-terminal His6 tag, as described
(26). SArGranA was constructed similarly, but without the
enterokinase site and with the active site Ser replaced by Ala.
Recombinant proteins were purified from bacterial pellets by
Ni2+ chelation, as described (26).
Affinity chromatography with SArGranA
Purified SA rGranA (4 mg) was coupled to 1 ml of Affi-Gel 10
(Bio-Rad, Richmond, CA) to produce an affinity matrix. Cytoplasmic
extracts prepared from 1 x 109 K562 cells
treated with Nonidet P-40 lysis buffer (0.5% Nonidet P-40, 25 mM KCl,
5 mM MgCl2, 1 mM PMSF, and 10 mM Tris-HCl, pH 7.6) were
applied to the column, washed with 1 M NaCl in lysis buffer, and eluted
with 6 M urea. Protein-containing fractions were analyzed by SDS-PAGE.
Protein bands at 27 and 53 kDa in the 6 M urea eluate were subjected to
tryptic digest and peptide sequencing performed by Harvard
Microchemistry Facility.
Cell lines
K562, HL60, and Jurkat cells were obtained from American Type Culture Collection (Rockville, MD). YT-Indy was a kind gift of Z. Brahmi (Indiana University School of Medicine, Indianapolis, IN). B lymphoblastoid cell lines (BLCL) were produced from EBV-infected PBMC by standard methods. T cell lines were generated by stimulating density-separated PBMC at 5 x 105/ml with 2 µg/ml phytohemagglutinin P (Difco, Detroit, MI) in T cell medium (RPMI 1640 supplemented with 2 mM glutamine, 2 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 50 µM ß-mercaptoethanol, and 15% FCS) to which was added 300 IU/ml human rIL-2 (Cetus, Emeryville, CA). Lymphokine-activated killer (LAK) cell lines were produced by culturing PBMC in T cell medium with 1000 IU/ml human rIL-2 for 2 to 3 wk. The LAK and T cell lines are predominantly CD3+CD8+ T cells.
Immunoblot
Electrophoresed samples were transferred to nitrocellulose membranes, blocked overnight with 5% nonfat milk and 0.05% Tween in TBS, and incubated for 1 h with a 1/2000 dilution of anti-hsp27 polyclonal rabbit sera (the kind gift of M. Mendelsohn, New England Medical Center, Boston, MA), or mouse mAb G3.1 (Stessgen, Victoria, B.C.), or 1/2000 dilution of anti-hsp70 mAb BB70 (Stressgen), or 1/500 dilution of rabbit anti-PHAP II N-terminal Ab (a kind gift of T. Copeland (26)) in 5% milk in Tween-TBS. Washed blots were incubated for 1 h with a 1/5000 dilution of anti-rabbit or anti-mouse Ig horseradish peroxidase (Amersham, Arlington Heights, IL), rinsed, and visualized by chemiluminescence with Luminol/Enhancer Solution (Pierce, Rockford, IL).
Coprecipitation with nickel resin
K562 cells (1 x 106 cell equivalents) were lysed in 1 ml of 0.1% Nonidet P-40, 1 mM PMSF, and 50 mM Tris-HCl, pH 8, for 30 min at 4°C and microfuged for 10 min at 12,000 rpm. The soluble lysates were incubated with 5 µg of either the proenzyme or the enterokinase-treated active form of rGranA and 20 µl of a 70% slurry of charged nickel resin in nickel resin-binding buffer (5 mM imidazole, 500 mM NaCl, and 20 mM Tris-HCl, pH 7.9) at 4°C for 2 h. Samples were washed five times with nickel resin-binding buffer, boiled in SDS sample-loading buffer, separated by SDS-PAGE on 15% polyacrylamide gels, and analyzed by immunoblot.
Heat shock of cell lines and separated PBMC
Approximately 5 to 10 x 105 cells were incubated for 1 h at 42°C, and then returned to 37°C for the indicated times. Cytoplasmic lysates were prepared as above at 5 x 104 cells/µl lysis buffer. For flow cytometry, cells were fixed and permeabilized using the Caltag Laboratories (Burlingame, CA) Fix and Perm Kit, according to the manufacturer’s protocol. Fixed cells were incubated for 15 min at RT with either 1/200 anti-hsp27 mAb G3.1 or 1/25 mouse IgG1 isotype-matched control Ab (Coulter, Hialeah, FL). After washing with 5 ml HBSS, cells were stained with 1/25 PE-conjugated F(ab')2 goat anti-mouse Ig (Dako, Carpenteria, CA). After two further washes, PBMC were resuspended in PBS and stained with FITC- or Cy5-conjugated mAb to cell surface markers CD8, CD4, CD14, CD16, and CD20 (Immunotech, Westbrook, ME). The washed cell lines and the costained PBMC were resuspended in FACS buffer (2% FCS, 0.2 mg/ml NaN3 in PBS) with 1% formaldehyde before analysis. Flow-cytometry analysis was performed on tightly gated lymphocyte and monocyte populations using FACScalibur (Becton Dickinson, Mountain View, CA).
LAK assay
Effector LAK cell lines (1 x 105 per condition) were incubated in 200 µl RPMI medium supplemented with 10% FCS and 1 mM EGTA in Eppendorf tubes for 30 min at 37°C, then mixed with an equal number of target cells (K562) and pelleted. After gentle addition of 1 µl 1 M CaCl2 to a final concentration of 5 mM Ca2+, cells were harvested at subsequent time points and lysed at 4°C for 30 min in 20 µl Nonidet P-40 lysis buffer, to which was added 0.5 mg/ml EDTA, 10 µg/ml leupeptin, 10 µg/ml pepstatin, 1 µg/ml aprotinin, 1 mg/ml Pefabloc, and 10 µg/ml E64 (Boehringer Mannheim, Indianapolis, IN). The insoluble precipitate, including nuclei, was washed twice in Nonidet P-40 lysis buffer + 1% Triton X-100 and resuspended in 20 µl 0.1% Nonidet P-40 and 10 mM Tris-HCl, pH 8 (containing the same inhibitors as above), before adding 5 µl 5x SDS sample buffer. Samples were boiled for 5 min before electrophoresis and blotting with anti-hsp27 antiserum. Control samples, in which CaCl2 or LAK cells were not added, were analyzed in tandem. Blots were stripped and reprobed with polyclonal rabbit antiserum to moesin (a gift of E. Remold-O’Donnell, The Center for Blood Research, Harvard Medical School, Boston, MA).
Immunofluorescence microscopy
COS cells, plated at subconfluence and grown for 1 to 2 days on slides (Nunc), were incubated with 5 µg/ml Con A (Sigma, St. Louis, MO) before adding LAK cells at a 1:1 ratio. In some experiments, LAK cells were preincubated for 20 to 30 min in 200 µl complete medium containing 1 mM EGTA. After 20 to 30 min, 1 µl 1 M CaCl2 was added gently by pipetman so as not to disrupt LAK cell/target cell conjugates to initiate granule-mediated cytolysis. Twenty minutes later, cells were fixed and permeabilized using the Caltag Laboratories Fix and Perm Kit, according to the manufacturer’s protocol. In other experiments, LAK cells were added in complete medium without EGTA, and the slides were centrifuged for 5 min at 866 x g to hasten conjugate formation and incubated for an additional 15 to 20 min at 37°C before fixation. In parallel, adherent COS cells on replicate slides were labeled with 51Cr for 1 h and washed before adding LAK cells, as above. Percentage of specific cytotoxicity was assayed from culture supernatants harvested at 15 min and 30 min after centrifugation. To visualize hsp27, cells were stained as above. On some slides, cells were costained with a 1/100 dilution of rhodamine phalloidin (Molecular Probes, Eugene, OR). Stained slides were analyzed using a Zeiss Axiophot fluorescent microscope.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We previously used a SArGranA affinity column to identify two
ubiquitously expressed proteins, PHAP I and II, as candidate
participants in the granzyme A pathway of cell death. We were able to
confirm the PHAP II interaction by coimmunoprecipitating PHAP II with
inactive granzyme A from cytoplasmic lysates, and demonstrating that
PHAP II is a substrate of active rGranA and that it is degraded within
minutes of CTL attack (26). Further study of the potential interaction
of granzyme A with PHAP I awaits the development of PHAP I Ab and
recombinant protein. The PHAP I and II proteins were eluted from the
SArGranA affinity column by extraction in the presence of 0.2 to 1 M
NaCl. To identify additional proteins that might be involved in the
granzyme A pathway, we treated the K562 cytoplasmic lysate-loaded
SArGranA column with progressively harsher eluting agents. No
additional proteins eluted from the column with glycine-HCl or
radioimmunoprecipitation assay buffer (data not shown), but 6 M urea
eluted two new proteins of 27 and 53 kDa (Fig. 1
A). An additional less
prominent band migrating with an apparent m.w. of 70 kDa also eluted
under these conditions. The 27- and 53-kDa proteins were analyzed by
tryptic digestion and N-terminal sequencing. The tryptic digest HPLC
chromatograms of p27 and p53 were identical. Three analogous peaks of
the two proteins were analyzed by mass absorption laser densitometry
and found to have equivalent m.w., suggesting that p53 is a dimer of
p27. Three p27 peptides (of 5, 8, and 10 amino acids) were identical to
sequences of the heat shock protein hsp27. The identification of p27
and p53 as the monomer and dimer of hsp27 was confirmed by
immunoblotting with a polyclonal anti-hsp27 rabbit antiserum (gift
of M. Mendelsohn) (Fig. 1B). Because of the
identification of p27 and p53 with a heat shock protein, we surmised
that p70 might correspond to hsp70. In fact, probing the 6 M urea
eluate with antisera to hsp70 identifies the 70-kDa band as hsp70 (Fig. 1C).
|
The harsh elution conditions required to strip hsp27 from the
granzyme column suggest a high affinity interaction. To confirm the
interaction of hsp27 with granzyme A in cells and to determine whether
hsp27 might be a substrate of granzyme A, we added His-tagged active
rGranA and inactive pro-rGranA (not treated with enterokinase) to K562
cell extracts and precipitated His-tagged granzyme A with nickel resin.
When the precipitates were analyzed by SDS-PAGE and immunoblotting with
hsp27 antiserum, the monomeric and dimeric hsp27 bands were visualized
in samples to which rGranA or pro-rGranA was added, but not in control
samples to which no granzyme was added (Fig. 2A). To confirm that
hsp27 is not a substrate of granzyme A, K562 lysates were incubated
with 0.56 µM rGranA, SArGranA, or pro-rGranA for 1 h at
37°C and analyzed by immunoblot probed with antisera against hsp27
and PHAP II. PHAP II was cleaved by the active rGranA to produce the
25-kDa N-terminal fragment, as previously reported (26), but hsp27
remained unchanged after granzyme A exposure. These results verify the
interaction of granzyme A and hsp27 and demonstrate that hsp27 is not a
substrate for cleavage by granzyme A.
|
Hsp27 has been reported to be a ubiquitous protein up-regulated in
response to heat shock and other stresses. However, as shown in Figure 2
, hsp27 was not detected by immunoblot in lysates from LAK cells. We
therefore investigated by flow cytometry and immunoblot the
expression of hsp27 in PBMC and cell lines of various hemopoietic
lineages. Analysis of freshly isolated permeabilized human PBMC by flow
cytometry revealed abundant hsp27 in monocytes, but no detectable hsp27
above background in B or T lymphocytes (Fig. 3A, Table I). Ten hemopoietic cell lines were also
analyzed for hsp27 expression. Hsp27 was expressed abundantly in the
myeloid cell line HL60 and in the erythroleukemia cell line K562, as
well as in two of three EBV-transformed BLCL. However, in two
PHA-stimulated T cell lines, a LAK cell line and Jurkat and YT-Indy
cell lines, no hsp27 was detected by immunoblot. To confirm these
results, the cell lines were permeabilized and stained for hsp27 and
analyzed by flow cytometry (Table II).
The mean fluorescence intensity (MFI) corresponded to the immunoblot
results. Cells with MFIs less than 46 were negative on immunoblot,
whereas cells with MFIs above 97 were positive. The T and NK cell lines
had MFIs between 7 and 15, not much above background control Ig levels
of 3 to 5. The positive B and myeloid cell lines stained considerably
brighter with MFIs of 94 to 390. Therefore, T cells may differ from
other hemopoietic cells in expressing barely any hsp27.
|
|
|
B). Although no hsp27 was detectable in freshly
isolated PBL 1 h after heat shock (data not shown), low levels of
protein were detected in both T and B cell populations 14 h after
heat shock. However, expression in cytolytic cell populations
expressing CD8 or CD16 was lower than that of B cells or CD4 T cells
(Table I). Fourteen hours after heat shock, hsp27 became detectable by
immunoblot in the previously negative BLCL and in one of the T cell
lines (Fig. 3C). By flow cytometry, hsp27 increased
somewhat in all of the T cell lines, but not in the NK cell line
YT-Indy (Table II). The T cell lines, however, consistently expressed
2- to 12-fold less hsp27 after heat shock than the other cell lines
studied. Hsp27 coalesces into long filamentous strands within minutes of CTL attack
We have found that another granzyme A-binding protein, PHAP II,
translocates to the nucleus and is degraded within minutes of CTL
attack (26) (Beresford et al., manuscript in preparation). To determine
changes in cellular distribution of hsp27 during CTL attack, we added
Ca2+ to K562 targets mixed with human
EGTA-preincubated LAK cells. Anti-hsp27 immunoblots of nuclear and
cytoplasmic lysates were obtained before and at serial times after
Ca2+ was added (Fig. 4A). Hsp27 is present
only in the cytoplasmic lysate of K562 cells and is undetectable in the
LAK cells. Within 5 minutes of adding Ca2+, hsp27 became
detectable in the insoluble pellet and was virtually completely gone
from the soluble cytoplasmic lysate within 10 min. However, the control
cytoskeletal protein moesin remained in the cytoplasmic fraction during
the LAK attack. The addition of Ca2+ without LAK cells to
EGTA-treated K562 cells also did not change the localization of hsp27
(Fig. 4B).
|
and 6).
Because immunofluorescence staining is better visualized on adherent
cells, we took advantage of the fact that LAK cells lyse Con A-treated
targets, such as COS cells, which are not normally LAK targets.
Lectin-mediated CTL attack was initiated by adding Ca2+ to
EGTA-preincubated LAK cells mixed with adherent Con A-treated COS
target cells. Within 20 min of initiating granule exocytosis, the hsp27
coalesced from diffuse cytoplasmic staining to staining in long
filamentous strands that concentrate around the nuclear membrane,
similar to what occurs in heat shock (39, 40). The addition of
Ca2+ without effector T cells did not induce a change in
hsp27 localization (data not shown). When Ca2+-treated COS
and LAK cell mixtures were costained with phalloidin, there was a
collapse of the actin skeleton into filaments that coincide with those
staining for hsp27.
|
).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
ArGranA affinity column. Its binding to
the column was so strong that 6 M urea was required for elution.
Although we found that hsp27 is not a substrate for granzyme A, we were
able to validate a physiologic role of hsp27 in granzyme A-mediated
cell death by coprecipitating granzyme A with hsp27 from K562 cell
lysates and by showing a change in cellular localization of hsp27 from
diffuse cytoplasmic staining to association with newly formed F-actin
stress fibers within minutes of LAK attack. Although we have implicated
hsp27 in the granzyme A pathway of cell death, what role hsp27 plays in
this process remains to be elucidated. After exposure to a variety of
cellular stresses, hsp27 aggregates in so-called stress granules in
association with other cytoskeletal components and RNA (39, 40).
Immunoelectron microscopy localization of hsp27 after CTL attack or
granzyme A loading could determine whether similar structures are
observed during CTL attack. Hsp27 may be involved in the morphologic changes seen with granzyme A loading of target cells. The avian homologue of hsp27 has been shown to regulate the actin cytoskeleton by binding to the cap site of actin (41). The cytoskeletal effect of hsp27 is believed to be regulated by phosphorylation on Ser15, Ser78, and Ser82 in response to a variety of stimuli (35, 36, 37). Only the dephosphorylated form of hsp27 blocks actin polymerization into F-actin. Hsp27 is phosphorylated after cellular activation or stress, allowing G-actin to polymerize into filamentous F-actin. The formation of filamentous actin stress fibers is inhibited by overexpression of a nonphosphorylatable mutant form of hsp27 (35, 42). PP2A is thought to play a significant role in the regulation of the phosphorylation state of hsp27 since it dephosphorylates hsp27 in vitro and phosphorylation of hsp27 is increased in cells treated with the specific PP2A inhibitor, okadaic acid (43). The two other proteins, PHAP I and II, which we have identified as participants in the granzyme A pathway, have been shown to be inhibitors of PP2A (28, 32). A proposed role for PP2A in a third molecule implicated in this pathway is intriguing.
After treatment of cells with some activation or stress stimuli, hsp27 also translocates to or near the nucleus, but the chaperone function is thought to be phosphorylation independent (40, 44, 45). A possible role for hsp27 in endonuclease activation needs to be explored. G-actin binding of DNase I, believed to be an important activator of DNA degradation during apoptosis, is known to inhibit its endonuclease activity (46, 47, 48). One possible hypothesis is that hsp27, phosphorylated during CTL attack, induces F-actin polymerization that liberates DNase I from G-actin inhibition.
Hsp27 might also be involved in the transport of granzyme A or granzyme A pathway proteins such as the PHAPs to the nucleus during CTL attack. We have not yet determined whether there is a direct interaction of hsp27 with either of the PHAP proteins. Interestingly, PHAP I may play a role in other intracellular trafficking changes that occur during apoptosis. PHAP I has been identified recently as a modulator of movement of cytoplasmic organelles along microtubules by binding to microtubulin-associated proteins and causing their dissociation from microtubules (29).
A possible role for hsp27 in apoptosis has been suggested in prior
reports. Constitutive overexpression of hsp27 in L929 cells protects
against fas-mediated and chemical-induced cell death (49, 50). On the other hand, overexpression of hsp27 in MCF-7 breast cancer
cells has been reported to increase significantly susceptibility to
lysis by T cells (38).
Hsp27 has been thought to be a ubiquitous protein up-regulated in response to heat shock and other stresses. However, we have found that it is expressed barely, if at all, in freshly isolated PBL, and is only modestly up-regulated in T cells and NK cells after heat shock. If hsp27 plays an important role in cell-mediated lysis, then its absence or low level in cells with cytolytic capacity may contribute to their relative resistance to granule-mediated lysis (51).
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Judy Lieberman, The Center for Blood Research, 800 Huntington Avenue, Boston, MA 02115. E-mail address:
3 Abbreviations used in this paper: PHAP, putative human histocompatibility leukocyte antigen-associated protein; BLCL, B lymphoblastoid cell line; hsp, heat shock protein; PHA-P, phytohemagglutinin P LAK, lymphokine-activated killer cell; MFI, mean fluorescence intensity; pro-rGranA, recombinant human granzyme A before cleavage of engineered propeptide; rGranA, recombinant human granzyme A; SArGranA, mutant recombinant granzyme A with active site serine replaced by alanine.
Received for publication November 3, 1997. Accepted for publication March 3, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  E. Schmitt, M. Gehrmann, M. Brunet, G. Multhoff, and C. Garrido Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy J. Leukoc. Biol., January 1, 2007; 81(1): 15 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Bredemeyer, P. E. Carrigan, T. A. Fehniger, D. F. Smith, and T. J. Ley Hop Cleavage and Function in Granzyme B-induced Apoptosis J. Biol. Chem., December 1, 2006; 281(48): 37130 - 37141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Dressel, C. Grzeszik, M. Kreiss, D. Lindemann, T. Herrmann, L. Walter, and E. Gunther Differential Effect of Acute and Permanent Heat Shock Protein 70 Overexpression in Tumor Cells on Lysability by Cytotoxic T Lymphocytes Cancer Res., December 1, 2003; 63(23): 8212 - 8220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gross, W. Koelch, A. DeMaio, N. Arispe, and G. Multhoff Cell Surface-bound Heat Shock Protein 70 (Hsp70) Mediates Perforin-independent Apoptosis by Specific Binding and Uptake of Granzyme B J. Biol. Chem., October 17, 2003; 278(42): 41173 - 41181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wyttenbach, O. Sauvageot, J. Carmichael, C. Diaz-Latoud, A.-P. Arrigo, and D. C. Rubinsztein Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin Hum. Mol. Genet., May 1, 2002; 11(9): 1137 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Paul, F. Manero, S. Gonin, C. Kretz-Remy, S. Virot, and A.-P. Arrigo Hsp27 as a Negative Regulator of Cytochrome c Release Mol. Cell. Biol., February 1, 2002; 22(3): 816 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Beresford, D. Zhang, D. Y. Oh, Z. Fan, E. L. Greer, M. L. Russo, M. Jaju, and J. Lieberman Granzyme A Activates an Endoplasmic Reticulum-associated Caspase-independent Nuclease to Induce Single-stranded DNA Nicks J. Biol. Chem., November 9, 2001; 276(46): 43285 - 43293. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Gain, G. Thuret, C. Chiquet, J. M. Dumollard, J. F. Mosnier, and L. Campos In situ immunohistochemical study of Bcl-2 and heat shock proteins in human corneal endothelial cells during corneal storage Br J Ophthalmol, August 1, 2001; 85(8): 996 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. De, K. M. Kodys, B. S. Yeh, and C. Miller-Graziano Exaggerated Human Monocyte IL-10 Concomitant to Minimal TNF-{alpha} Induction by Heat-Shock Protein 27 (Hsp27) Suggests Hsp27 Is Primarily an Antiinflammatory Stimulus J. Immunol., October 1, 2000; 165(7): 3951 - 3958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Dressel, L. Elsner, T. Quentin, L. Walter, and E. Gunther Heat Shock Protein 70 Is Able to Prevent Heat Shock-Induced Resistance of Target Cells to CTL J. Immunol., March 1, 2000; 164(5): 2362 - 2371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Guzik, J. Dobrucki, and J. Pryjma Heat-Shocked Monocytes Are Resistant to Staphylococcus aureus-Induced Apoptotic DNA Fragmentation due to Expression of HSP72 Infect. Immun., August 1, 1999; 67(8): 4216 - 4222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Podack How to induce involuntary suicide: The need for dipeptidyl peptidase I PNAS, July 20, 1999; 96(15): 8312 - 8314. [Full Text] [PDF]
|
|
|
|
|
|
H. Lambert, S. J. Charette, A. F. Bernier, A. Guimond, and J. Landry HSP27 Multimerization Mediated by Phosphorylation-sensitive Intermolecular Interactions at the Amino Terminus J. Biol. Chem., April 2, 1999; 274(14): 9378 - 9385. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
